(Q38040697)

27 August 2017

Individualization of drug therapy: history, present state, and opportunities for the future (English)

1 reference

27 August 2017

L J Lesko

1

1 reference

PubMed ID

22948891

27 August 2017

S Schmidt

series ordinal

2

1 reference

PubMed ID

22948891

27 August 2017

language of work or name

English

0 references

publication date

5 September 2012

1 reference

Clinical Pharmacology & Therapeutics

27 August 2017

1 reference

27 August 2017

92

1 reference

27 August 2017

4

1 reference

27 August 2017

458-466

1 reference

Evolving ways that drug therapy is individualized.

27 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.113

Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.113

Therapeutic drug monitoring of voriconazole and posaconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.113

Pharmacogenetics and Pharmacogenomics in Drug Development and Regulatory Decision Making: Report of the First FDA‐PWG‐PhRMA‐DruSafe Workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.113

Genomic and personalized medicine: foundations and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.113

HLA-B*5701 screening for hypersensitivity to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.113

Personalized medicine: elusive dream or imminent reality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.113

The genetic basis for cancer treatment decisions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.113

Enrichment of clinical study populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.113

Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.113

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.113

Threats to the validity of clinical trials employing enrichment strategies for sample selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.113

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.113

Individualizing hormone therapy to minimize risk: accurate assessment of risks and benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.113

Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.113

Model-based drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.113

Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.113

Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.113

Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.113

A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.113

Physiologically-based pharmacokinetics in drug development and regulatory science

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.113

The effects of dose staggering on metabolic drug-drug interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.113

Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.113

Systems biology: Metabonomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.113

Personal omics profiling reveals dynamic molecular and medical phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.113

Clinical application of pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.113

7 January 2021

What is clinical utility and why should we care?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.113

7 January 2021

DNA, drugs and chariots: on a decade of pharmacogenomics at the US FDA

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2012.113

7 January 2021

https://api.crossref.org/works/10.1038%2FCLPT.2012.113

1 reference

7 January 2021

Identifiers

DOI

10.1038/CLPT.2012.113

1 reference

27 August 2017

1 reference

PubMed ID

22948891